News
PNT2002 is a would-be competitor to Novartis’ Pluvicto (lutetium Lu 177 vipivotide tetraxetan), another PSMA-directed radioligand that was approved by the FDA last year as a treatment for ...
which already sells two radiopharma drugs – Lutathera lutetium (Lu 177 dotatate) for NETs and prostate cancer treatment Pluvicto (lutetium Lu 177 vipivotide tetraxetan) – and has a string of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback